×
About 24,716 results
Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B, et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical expertise requirements. The surrogate index of triglycerides and glucose (TyG index) has been validated in non-rheumatic populations, showing adequat...

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/NEJMoa1912388?query=featured_home
New England Journal of Medicine; Tardif JC et al

Nov 16th, 2019 - Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.

Scientists design device for oral delivery of injections
https://www.nih.gov/news-events/nih-research-matters/scientists-design-device-oral-delivery-injections

Oct 28th, 2019 - Biologic drugs are complex medications produced from living organisms or their parts. They include vaccines and drugs to treat conditions like rheumatoid arthritis, psoriasis, and cancer. Some biologic drugs, like insulin, can only be delivered by injection. If taken by mouth, stomach acid would destroy the drug before it could take effect.

FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-rare-diseases-cause-inflammation-small-blood-vessels

Sep 26th, 2019 - The U.S. Food and Drug Administration today approved Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids (steroid hormones). It is the first approved treatment for children with these rare vasculitis diseases, in which a patient’s small blood vessels become infla...

Sjögren’s Syndrome in Systemic Lupus Erythematosus - a Subset Characterized by a Systemic Inflammatory State
http://www.jrheum.org/content/early/2019/09/11/jrheum.190250
J Rheumatology; Ruacho G, et al

Sep 20th, 2019 - Secondary Sjögren’s syndrome (SLE-sSS) is an often-neglected subset of patients with Systemic lupus erythematosus (SLE). Furthermore, primary Sjögren’s syndrome overlaps and can be difficult to delineate from SLE. To shed light on the SLE-sSS subset, we investigated a large and well-characterized SLE cohort comparing patients with SLE-sSS versus SLE patients without SS (SLE-nonsSS) and controls.

Psoriatic Arthritis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK547710/

Sep 19th, 2019 - Psoriatic arthritis (PsA) is chronic inflammatory arthritis associated with psoriasis (PsO) and found in about 20 to 30% of such patients.[1] It shares many clinical features with other spondyloarthropathies and also rheumatoid arthritis (RA). It is usually seronegative, but a small percentage of patients may be positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodi...

FDA approves first treatment for patients with rare type of lung disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease

Sep 5th, 2019 - The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition.

Unraveling the Safety Profile of Proton-Pump Inhibitors
https://www.jwatch.org/na49660/2019/08/19/unraveling-safety-profile-proton-pump-inhibitors
Journal Watch;

Aug 19th, 2019 - Proton-pump inhibitors (PPIs) provide important clinical benefits for many patients. However, observational studies have suggested an association between PPI use and a variety of adverse events, including dementia, osteoporosis, bone fractures, micronutrient deficiencies, pneumonia, spontaneous bacterial peritonitis, kidney disease, and enteric infections. We have observed that some patients wi...

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor F...
https://news.abbvie.com/news/press-releases/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm?_ga=2.79140499.665850950.1566223698-1470367535.1566223698

Aug 15th, 2019 - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).1 R...

ACG Clinical Guideline: Hereditary Hemochromatosis
https://journals.lww.com/ajg/Fulltext/2019/08000/ACG_Clinical_Guideline__Hereditary_Hemochromatosis.11.aspx
Kowdley, K. et. al.

Aug 1st, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic testing for HH has made possible confirmation of the diagnosis for most patients. Several genotype-phenotype correlation studies have clarified the diffe...

FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses
https://www.fda.gov/news-events/press-announcements/fda-clears-new-indications-existing-lyme-disease-tests-may-help-streamline-diagnoses

Jul 28th, 2019 - Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared today are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process ...

FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)
https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and

Jul 25th, 2019 - The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. In addition, the approved use of tofacitinib for ulcerative colitis will be limited to certain patients who are not treated effectively or who experience severe...

Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose
https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death

Jul 25th, 2019 - AUDIENCE: Patient, Health Professional, Pharmacy, Gastroenterology, Rheumatology ISSUE: FDA has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of Xeljanz, Xeljanz XR (tofacitinib), which is used in patients with ulcerative colitis. In addition, the approved use of tofacitinib for ulcerative colitis will be limited to certain patients...

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. Please see below the full indicatio...

FDA Approves Pfizer’s Biosimilar, Ruxience™ (Rituximab-pvvr), For Certain Cancers And Autoimmune Conditions
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions

Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).2 “Biosimilars like RUXIENCE h...

FDA approves first generics of Lyrica
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-lyrica

Jul 21st, 2019 - On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgi...

Rheumatoid arthritis - Genetics Home Reference - NIH
https://ghr.nlm.nih.gov/condition/rheumatoid-arthritis

Jul 15th, 2019 - Rheumatoid arthritis is a disease that causes chronic abnormal inflammation, primarily affecting the joints. The most common signs and symptoms are pain, swelling, and stiffness of the joints. Small joints in the hands and feet are involved most often, although larger joints (such as the shoulders, hips, and knees) may become involved later in the disease. Joints are typically affected in a sym...

Acupuncture for Pain
https://www.aafp.org/afp/2019/0715/p89.html
American Family Physician; Kelly, R. et. al.

Jul 14th, 2019 - Acupuncture has been increasingly used as an integrative or complementary therapy for pain. It is well-tolerated with little risk of serious adverse effects. Traditional acupuncture and nontraditional techniques, such as electroacupuncture and dry needling, often result in reported pain improvement. Multiple factors may contribute to variability in acupuncture's therapeutic effects, including n...

Does periodontitis represent a risk factor for rheumatoid arthritis? A systematic review and meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620730/
Therapeutic Advances in Musculoskeletal Disease; Ferreira, R. et. al.

Jul 8th, 2019 - Periodontitis is an inflammatory disease of dental supporting tissues (gingiva, periodontal ligament, and bone) and it has been suggested as a possible etiology for rheumatoid arthritis (RA). In this systematic review, we aim to verify if periodontitis represents a risk factor for RA. Electronic databases were consulted until March 2018 considering eligibility criteria focusing on: (P, particip...

Psoriatic arthritis - Genetics Home Reference - NIH
https://ghr.nlm.nih.gov/condition/psoriatic-arthritis

Jul 8th, 2019 - Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pi...

Machine learning approaches to predict lupus disease activity from gene expression data
https://www.nature.com/articles/s41598-019-45989-0
Scientific Reports; Kegerreis, B. et. al.

Jul 2nd, 2019 - The integration of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a significant challenge because of the high degree of heterogeneity among patients and study cohorts, especially those collected on different microarray platforms. Here we deployed machine learning approaches to integrate gene expression data from three SLE data sets and used it to classify...

National Psoriasis Foundation – Med Pro: Treat to Target
https://www.psoriasis.org/treatment-targets/providers

Jun 30th, 2019 - “It’s important to have treatment targets because, while we all think we’re doing the best job we possibly can for our patients, having goals that we can objectively measure ourselves against keeps us from growing complacent,” says Abby Van Voorhees, M.D., chair of dermatology at Eastern Virginia Medical School and chair of NPF's medical board.

Resources | HUMIRA (adalimumab)
https://www.humiraconnect.com/psoriatic-arthritis/resources

Jun 27th, 2019 - See Important Safety Information, including BOXED WARNING.

IDSA/AAN/ACR Draft Lyme Disease Guidelines
https://www.idsociety.org/practice-guideline/Lyme-Disease-Guideline-Public-Comments/

Jun 26th, 2019 - The Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) are now accepting comments on the “2019 Draft Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease.” We are looking for feedback from not only physicians and healthcare professionals, but also individuals affected by Lyme disease, such as patients,...

Dosing | HUMIRA (adalimumab)
https://www.humiraconnect.com/psoriatic-arthritis/dosing

Jun 26th, 2019 - Dosing See Important Safety Information, including BOXED WARNING.

Arthritis Prevalence Statistics
https://www.rheumatology.org/Learning-Center/Statistics/Prevalence-Statistics

Jun 26th, 2019 - View overall prevalence of arthritis and rheumatic diseases as well as prevalence among specific racial and ethnic groups.

National Resource Center on Lupus | Lupus Foundation of America
https://www.lupus.org/resources

May 22nd, 2019 - Your go-to source for lupus information, resources, and support.

Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560976/
RMD Open;

May 22nd, 2019 - Aims To determine whether the proportion of time systemic lupus erythematosus patients achieve remission/low disease activity state (LDAS) is associated with a better quality of life (QoL). Patients and methods Patients from a well-established multiethnic, multicentre US cohort were included: remission: Systemic Lupus Activity Measure (SLAM) score=0, prednisone≤5 mg/day and no immunosuppre...

Primary care and psoriatic disease
https://www.psoriasis.org/health-care-providers/primary-care

May 12th, 2019 - Psoriasis is a chronic, inflammatory disease that affects over 8 million Americans. Psoriasis can profoundly decrease quality of life without appropriate treatment. Additionally, psoriasis is associated with comorbidities including cardiovascular disease, inflammatory arthritis, depression and others. Primary care providers play an important role in both managing overall health and screening...

DEET | US EPA
https://www.epa.gov/insect-repellents/deet

May 8th, 2019 - Safety Review of DEET (chemical name, N,N-diethyl-meta-toluamide) is the active ingredient in many repellent products. It is widely used to repel biting pests such as mosquitoes and ticks. Every year, an estimated one-third of the U.S. population use DEET to protect them from mosquito-borne illnesses like West Nile Virus, the Zika virus or malaria and tick-borne illnesses like Lyme disease and ...

Guidance for Clinicians: Recommendations for Patients after a Tick Bite
https://www.cdc.gov/lyme/resources/FS-Guidance-for-Clinicians-Patients-after-TickBite-508.pdf

Apr 30th, 2019 - Antimicrobial prophylaxis for the prevention of Lyme disease (Table 1) following tick bite may be beneficial in certain circumstances. A single dose of doxycycline can lower the risk of Lyme disease when: The tick bite occurred in a state where Lyme disease incidence is high

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States
http://www.samsungbioepis.com/en/newsroom/detail/FDA-Approves-ETICOVO-Samsung-Bioepis-Second-Anti-TNF-Medicine.html

Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis. ETICOVO™ is Samsung Bioepis’ secon...

Pediatric Systemic Lupus Erythematosus Workup
https://emedicine.medscape.com/article/1008066-workup

Apr 26th, 2019 - The initial laboratory evaluation should include a complete blood count (CBC) with platelets and reticulocyte count; a complete chemistry panel to evaluate electrolytes, liver, and kidney function; urine analysis; and a measure of acute phase reactants (eg, erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]).

Lupus Erythematosus - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK535405/

Apr 19th, 2019 - The acute form of systemic lupus erythematosus (SLE) differs from the chronic form. It disseminates differently, and it is highly fatal. Kaposi was the first in recognizing SLE in 1872, and then Pernet described it in 1908. Before that time SLE was considered to be a non-fatal disfiguring skin disease. It is now to be considered a chronic inflammatory disease characterized by a course of altern...

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
https://wwwext.amgen.com/media/news-releases/2019/04/fda-approves-evenity-romosozumabaqqg-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture/

Apr 8th, 2019 - Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (...

The Psoriasis And Psoriatic Arthritis Pocket Guide
https://www.psoriasis.org/sites/default/files/npf_pocketguide_2018_0010.pdf
Van Voorhees

Apr 3rd, 2019 - This is the fifth edition of The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. Since the publication of the fourth edition, several new psoriatic disease treatments have become available, and the medical community has more experience with biological treatments in the management of psoriatic disease. The National Psoriasis Foundation has revis...

Direct-to-consumer genetic testing
https://www.ama-assn.org/delivering-care/precision-medicine/direct-consumer-genetic-testing

Apr 2nd, 2019 - Types of DTC genetic tests A broad range of genetic test types are offered DTC, including: Carrier testing for diseases such as cystic fibrosis and hemochromatosis Pharmacogenomic testing Testing for predisposition to complex diseases such as hereditary cancers, cardiovascular disease and depression Whole exome or genome sequencing Testing to determine ancestry

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
https://jnccn.org/view/journals/jnccn/17/4/article-p302.xml
Benson, A. et. al.

Mar 31st, 2019 - Incidence and mortality rates for cancer overall are declining, but both incidence and mortality rates for hepatocellular carcinoma (HCC) are increasing.1,2 Risk factors for development of HCC include infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), and cirrhosis of the liver (eg, alcohol cirrhosis).3 Metabolic disorders (ie, obesity, diabetes, impaired glucose metabolism,...

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
https://ard.bmj.com/content/78/6/736
Annals of the Rheumatic Diseases; Fanouriakis, A. et. al.

Mar 28th, 2019 - Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007–12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydrox...

TRILURON™ - P180040
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm635176.htm

Mar 25th, 2019 - TRILURON™ is a single-use syringe prefilled with sodium hyaluronate. Hyaluronate is a chemical found in the body, and it is present in joint tissues and in the fluid that fills the joints. The body's own hyaluronate acts like a lubricant and a shock absorber in the joint, and it is needed for the joint to work properly. In osteoarthritis, there may not be enough hyaluronate, and there may be a ...

Filgotinib
https://www.glpg.com/filgotinib

Mar 6th, 2019 - Filgotinib is a highly selective JAK1 inhibitor, discovered and developed by Galapagos using its target and drug discovery technology platform. In more than 1,600 patient years of rheumatoid arthritis (RA) and Crohn's disease clinical study experience, filgotinib has shown a rapid onset of action, potentially best-in-class efficacy and favorable findings on safety and tolerability. From a regul...

Infection and Lupus: Which Causes Which?
https://link.springer.com/article/10.1007/s11926-016-0561-4
Current Rheumatology Reports; Doaty, S. et. al.

Mar 6th, 2019 - Infection is a leading cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Dysfunction of the innate and adaptive immune systems increases the risk of infection in patients with SLE. Infectious agents have also been theorized to play a role in the pathogenesis of SLE. This article summarizes our current knowledge of the infectious risk SLE patients face as a ...

Arthritis Risk Factors | CDC
https://www.cdc.gov/arthritis/basics/risk-factors.htm

Mar 5th, 2019 - Learn about common arthritis risk factors. arthritis, arthritis relief, manage arthritis, arthritis management, arthritis self-management, joint pain, arthritis pain, arthritis information, CDC arthritis, managing arthritis, arthritis risk factors, arthritis risk

Lupus - Lab Tests
https://labtestsonline.org/conditions/lupus

Mar 4th, 2019 - Lupus is a chronic, inflammatory autoimmune disorder. Diagnosis of lupus is usually made by the clinical evaluation of physical signs and symptoms in combination with lab tests.

Rheumatoid Arthritis (RA) | Arthritis | CDC
https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html

Mar 4th, 2019 - Basic information about rheumatoid arthritis, including common symptoms and treatment.

Osteoporosis (Secondary) - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK470166/
Ganesan, K. et. al.

Mar 1st, 2019 - Osteoporosis is a bone disorder which is characterized by a decrease in bone strength, resulting from reduced bone mineral density, microarchitectural disruption, and skeletal fragility, thereby causing an increased risk of fracture. Secondary osteoporosis, which occurs due to the presence of underlying disease or medications, can also lead to low bone mass, resulting in increased risk of fract...

Diseases and Conditions- Rheumatoid Arthritis
https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis

Feb 28th, 2019 - Rheumatoid arthritis (RA) is the most common type of autoimmune arthritis. It is caused when the immune system (the body’s defense system) is not working properly. RA causes pain and swelling in the wrist and small joints of the hand and feet.

Review of Rheumatoid Arthritis
https://www.uspharmacist.com/article/review-of-rheumatoid-arthritis
Rheumatoid Arthritis

Feb 14th, 2019 - Rheumatoid arthritis (RA) is a chronic disease affecting up to 1% of populations in developed countries. Certain genetic and environmental factors appear to promote the development of RA, but patients can present with heterogeneous signs and symptoms. The goals of any treatment for RA are the reduction of inflammation and remission of disease. Historic treatments, such as aspirin and colloidal ...

Gout Activity Score has predictive validity and is sensitive to change: results from the Nottingham Gout Treatment Trial (Phase II)
https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/key446/5306645
Chinchilla, S. et. al.

Feb 3rd, 2019 - Objectives To examine the predictive validity of the Gout Activity Score (GAS), its correlation with the Gout Impact Scale (GIS) and their sensitivity to change. Methods Data from a clinical trial in which participants with one or more gout flares in the previous year were recruited from primary care and randomized to nurse-led or continuing usual care were used in this study. GAS and GIS were ...